US equities |
META $642.62 ▲+0.00% MU $877.55 ▲+0.00% TSLA $372.22 ▲+0.00% SPCX $147.49 ▲+0.00% NVDA $210.96 ▲+0.00% NU $15.16 ▲+0.00% SNDK $1,238.03 ▲+0.00% NBIS $158.74 ▲+0.00%
FinancialContent

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

30.98 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Expert Ratings for Immunocore Hldgs ↗
 
Via Benzinga
News headline image
Recap: Immunocore Hldgs Q1 Earnings ↗
 
Via Benzinga
News headline image
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Analyst Ratings for Immunocore Hldgs ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Preview: Immunocore Holdings's Earnings ↗
 
Via Benzinga
News headline image
Immunocore Reveals First Data From HIV Infection Candidate Study ↗
 
Via Benzinga
News headline image
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Short Volatility Alert: Immunocore Hldgs ↗
On Friday, shares of Immunocore Hldgs (NASDAQ: IMCR) experienced volatile short activity. After the activity, the stock price went up +3.38% to $54.81. The overall sentiment for IMCR has been Bearish. 
Via Benzinga
News headline image
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immunocore to present four posters at AACR Annual Meeting 2023
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore Reports 2022 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers ↗
Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March. 
Via Investor's Business Daily
News headline image
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
3 Pharma Stocks That Will Mint Millionaires ↗
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. 
Via InvestorPlace
News headline image
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022 ↗
 
Via Benzinga
News headline image
Immunocore is awarded the Prix Galien France award for KIMMTRAK
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
From Immunocore Holdings Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >